Benitec selects new site for phase I/II hepatitis C trial of TT-034
The Duke clinical research unit is the early phase unit of the Duke Clinical Research Institute. Benitec chief executive officer Peter French said, "The TT-034 trial marks the
Canadian biotechnology company Zymeworks has signed an agreement to acquire Theravance Biopharma in a cash transaction valued at approximately $929m (C$1.32bn).
The research will leverage Tokyo Tech’s TSUBAME2.0 supercomputer for the discovery of drugs for patients suffering from dengue fever/dengue hemorrhagic fever. The first step of the collaborative research
Cartagenia’s BENCHlab CNV solution helps labs to deploy microarray testing for prenatal diagnosis, as well as a seamless transition from prenatal to continued post-natal follow-up. The product will